City of Hope Medical Center: Multiple Myeloma trials

The registry lists 35 Multiple Myeloma studies with City of Hope Medical Center as lead sponsor. 5 are open to participants now and 10 have results posted.

Phase 1 15Phase 2 16No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma PatientsRecruitingNCT07225738
• Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART StudyRecruitingNCT06052826Phase 2
• Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaRecruitingNCT06048250Phase 1
• Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT05363111Phase 1
• Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaRecruitingNCT04508790Phase 2
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• Leflunomide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02509052Phase 1/2Results posted
• Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT02119468Phase 1/2Results posted
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadTerminatedNCT01159067Phase 2Results posted
• Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 2Results posted
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerCompletedNCT00589563Phase 2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow TransplantCompletedNCT00530218Phase 2Results posted
• Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple MyelomaCompletedNCT00112827Phase 1/2Results posted
• Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple MyelomaCompletedNCT00004088Phase 2Results posted
• External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary DiseaseSuspendedNCT06572605Phase 1/2
• Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma SurvivorsCompletedNCT05142371Not applicable
• Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST StudyActive, not recruitingNCT04537871
• Leflunomide in Treating Patients With High-Risk Smoldering Multiple MyelomaWithdrawnNCT03952832Phase 2
• CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaSuspendedNCT03710421Phase 1
• Daratumumab After Stem Cell Transplant in Treating Patients With Multiple MyelomaActive, not recruitingNCT03346135Phase 2
• Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaCompletedNCT03311828Phase 1
• Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple MyelomaWithdrawnNCT03100877Phase 1/2
• Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic LeukemiaCompletedNCT02948283Phase 1
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple MyelomaCompletedNCT01163357Phase 1
• Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT01074060Phase 1
• Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell TransplantCompletedNCT00964821
• Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00962507Phase 1
• Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy VolunteersTerminatedNCT00952185Not applicable
• A Standardized Nursing Intervention Protocol for HCT PatientsCompletedNCT00951626Not applicable
• Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other DiseasesTerminatedNCT00813501
• Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to TreatmentTerminatedNCT00800150Phase 1
• Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell TransplantCompletedNCT00716911Not applicable